Effect of moxonidine on left ventricular hypertrophy in hypertensive patients

Journal of Clinical and Basic Cardiology

Volumn 4, Issue 1, 2001, Pages 61-65

  Haczynski, J ^a,d   Spring, A ^b   Przewlocka Kosmala, M ^b   Flasinski, J ^c  

^a Medical Department   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Institute of Martime Gdynia   (Poland)

^d Eli Lilly Polska Sp z oo   (Poland)

Author keywords

Arterial hypertension; Blood pressure; Echocardiography; Left ventricular hypertrophy; Left ventricular mass

Indexed keywords

MOXONIDINE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BRAIN ISCHEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; THICKNESS; TITRIMETRY; XEROSTOMIA;

EID: 0035020466     PISSN: 15612775     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Wall stress and patterns of hypertrophy in the human left ventricle
2. Relation of left venticular hemodynamic load and contractile performance to left venticular mass in hypertension
3. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: The Frammingham Study
4. Prognostic implication echocardiographically determined left ventricular mass in the Frammingham Heart Study
5. Left ventricular hypertrophy: Effect on survival
6. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
7. Coronary flow study in patients with left ventricular hypertrophy of the hypertensive type
8. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease
9. Coronary vascular changes in the progression and regression of hypertensive heart disease
10. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy
11. Vulnerability to ischemic ventricular arrhythmias in left ventricular hypertrophy. Editorial comment
12. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study
13. Coronary circulation in arterial hypertension
14. Changes of the left ventricular diastolic function in exercising dogs without and with ischemia
15. Heart rate and force-frequency effects on diastolic function of the left ventricle in exercising dogs
16. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats. Stereological studies on myocytes, capillaries, and cardiac interstitium
17. Moxonidine: Pharmacology, clinical pharmacology and clinical profile
18. Moxonidine: A review of safety and tolerability after seven years of clinical experience
19. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure
20. Moxonidine: A new antiadrenergic antihypertensive agent
21. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent
22. Drugs acting on imidazoline receptors. A review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection
23. Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine
24. Therapy of hypertension and metabolic syndrome: Today's standard and tomorrow's perspectives
25. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives
26. Safety and tolerability of moxonidine in the treatment of hypertension
27. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats (SHR) - Stereological studies on myocytes, capillaries, and cardiac interstitium
28. Regression of left ventricular hypertrophy
29. Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine
30. Vergleich der wirkungen von moxonidine und nifedipine auf die linksventrikuläre funktion bei monotherapie der essentiellen hypertonie
31. The Committee on M-mode standardisation of the American Society of Echocardiography Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements
32. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method
33. Participation of endogenous catecholamines in the regulation of left ventricular mass in progeny of hypertensive patients
34. Angiotensin II: Hemodynamic regulator or growth factor?
35. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: Critical role of AT1 receptor subtype
36. Left ventricular muscle mass and diastolic function in patients with essential hypertension under long-term clonidine treatment
37. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
38. Hypertensive coronary microcirculation effects of the imidazoline-receptor-agonist moxonidine
39. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy: Multicenter trial
40. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
41. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment